Search Free Newsletters

Pharma

Transforming health through business and innovation.

Vaccine makers are facing seismic changes in U.S. policy

ByCatherine Arnst

The weight loss drug boom has barely begun. How big can it get?

ByCatherine Arnst

Hims & Hers CEO fires back at Novo Nordisk after partnership collapses over knockoff Wegovy

Novo Nordisk cuts off Hims & Hers over knockoff Wegovy — and the stock plummets 27%

Weight loss drugs are blowing up the U.S. trade deficit. Trump is blaming Ireland

ByCatherine Baab

A $250 mistake seems set to cost Ozempic maker Novo Nordisk billions

Novo Nordisk's latest weight loss drug deal is with an AI-powered research firm

ByShannon Carroll

Dozens of states want to block 23andMe from selling DNA info

Pfizer and other drug companies make 'no commitments' to the White House on lower drug prices

ByMichael Barclay

Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next

ByShannon Carroll

Noom wants to be 'the Duolingo of health'

ByShannon Carroll

CVS and Express Scripts sued to block a new law restricting drug middlemen

How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

New U.S. drug prices doubled amid a shift toward treating rare diseases

ByKevin Williams

Cigna is putting a cap on weight loss drug costs

ByKevin Williams

Noom is offering smaller doses of compounded Wegovy for weight loss

ByShannon Carroll

23andMe just got bought out of bankruptcy

ByMichael Barclay

Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

ByCatherine Baab

Trump's push for lower drug prices is just asking Big Pharma to make less money

Eli Lilly stock sinks as pharma misses out on the market rally